PURPOSE: The purpose of this study was to compare the feasibility and outcomes of two-stage hepatectomy in patients with or without accompanying digestive surgery. METHODS: We analyzed prospectively data from 56 patients with colorectal liver metastases undergoing two-stage hepatectomy between 1995 and 2009. Patients undergoing associated digestive resection (group I, n = 32) were compared with patients without associated digestive surgery (group II, n = 17). RESULTS: The feasibility rate was 87.5% (49 patients). Neither the type and extent of hepatectomy nor the type of chemotherapy administered differed between the two groups. The median interval between hepatectomies was 1.79 and 2.07 months for groups I and II, respectively (not significant). One patient (group I) died of liver failure after the second hepatectomy. Postoperative morbidity rates were comparable: 37.5% (group I) vs. 35.5% (group II) after the first hepatectomy and 46.9% (group I) vs. 52.9% (group II) after the second hepatectomy. The median hospital stay after the first hepatectomy was longer in group I (13.5 days) than in group II (10 days) (P < 0.01). Median follow-up was 54 months. The median overall survival (OS) was 45.8 months, and 3- and 5-year OS were 58 and 31%, respectively. Median OS was longer for group II (58 months) than for group I (34 months) (P = 0.048). CONCLUSIONS: Digestive tract resection associated with two-stage hepatectomy does not increase postoperative mortality or morbidity nor does it lead to delay in chemotherapy or a reduction in cycles administered. The need for digestive tract surgery should not affect the surgical management of two-stage hepatectomy patients.
PURPOSE: The purpose of this study was to compare the feasibility and outcomes of two-stage hepatectomy in patients with or without accompanying digestive surgery. METHODS: We analyzed prospectively data from 56 patients with colorectal liver metastases undergoing two-stage hepatectomy between 1995 and 2009. Patients undergoing associated digestive resection (group I, n = 32) were compared with patients without associated digestive surgery (group II, n = 17). RESULTS: The feasibility rate was 87.5% (49 patients). Neither the type and extent of hepatectomy nor the type of chemotherapy administered differed between the two groups. The median interval between hepatectomies was 1.79 and 2.07 months for groups I and II, respectively (not significant). One patient (group I) died of liver failure after the second hepatectomy. Postoperative morbidity rates were comparable: 37.5% (group I) vs. 35.5% (group II) after the first hepatectomy and 46.9% (group I) vs. 52.9% (group II) after the second hepatectomy. The median hospital stay after the first hepatectomy was longer in group I (13.5 days) than in group II (10 days) (P < 0.01). Median follow-up was 54 months. The median overall survival (OS) was 45.8 months, and 3- and 5-year OS were 58 and 31%, respectively. Median OS was longer for group II (58 months) than for group I (34 months) (P = 0.048). CONCLUSIONS: Digestive tract resection associated with two-stage hepatectomy does not increase postoperative mortality or morbidity nor does it lead to delay in chemotherapy or a reduction in cycles administered. The need for digestive tract surgery should not affect the surgical management of two-stage hepatectomy patients.
Authors: M Karoui; L Vigano; P Goyer; A Ferrero; A Luciani; M Aglietta; C Delbaldo; S Cirillo; L Capussotti; D Cherqui Journal: Br J Surg Date: 2010-09 Impact factor: 6.939
Authors: Dennis A Wicherts; Rafael Miller; Robbert J de Haas; Georgia Bitsakou; Eric Vibert; Luc-Antoine Veilhan; Daniel Azoulay; Henri Bismuth; Denis Castaing; René Adam Journal: Ann Surg Date: 2008-12 Impact factor: 12.969
Authors: Robert Martin; Philip Paty; Yuman Fong; Andrew Grace; Alfred Cohen; Ronald DeMatteo; William Jarnagin; Leslie Blumgart Journal: J Am Coll Surg Date: 2003-08 Impact factor: 6.113
Authors: Andreas M Kaiser; Shlomo Israelit; Daniel Klaristenfeld; Paul Selvindoss; Petar Vukasin; Glenn Ault; Robert W Beart Journal: J Gastrointest Surg Date: 2007-12-20 Impact factor: 3.452
Authors: Robert C G Martin; Vedra Augenstein; Nathan P Reuter; Charles R Scoggins; Kelly M McMasters Journal: J Am Coll Surg Date: 2009-03-26 Impact factor: 6.113
Authors: Yun Shin Chun; Jean-Nicolas Vauthey; Dario Ribero; Matteo Donadon; John T Mullen; Cathy Eng; David C Madoff; David Z Chang; Linus Ho; Scott Kopetz; Steven H Wei; Steven A Curley; Eddie K Abdalla Journal: J Gastrointest Surg Date: 2007-09-11 Impact factor: 3.452
Authors: Guido Torzilli; René Adam; Luca Viganò; Katsunori Imai; Jeremias Goransky; Andrea Fontana; Christian Toso; Pietro Majno; Eduardo de Santibañes Journal: Liver Cancer Date: 2016-11-29 Impact factor: 11.740